Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 14;10(5):e0126364.
doi: 10.1371/journal.pone.0126364. eCollection 2015.

Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue

Affiliations

Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue

Mohamed Asrih et al. PLoS One. .

Abstract

Background/hypothesis: Beside its beneficial effects on weight loss, ketogenic diet (KD) causes dyslipidemia, a pro-inflammatory state involved in the development of hepatic steatosis, glucose intolerance and insulin resistance, although the latter is still being debated. Additionally, KD is known to increase fibroblast growth factor 21 (FGF21) plasma levels. However, FGF21 cannot initiate its beneficial actions on metabolism in these conditions. We therefore hypothesized and tested in the present study that KD may impair FGF21 signaling.

Methods/results: Using indirect calorimetry, we found that KD-fed mice exhibited higher energy expenditure than regular chow (RC)-fed mice associated with increased Ucp1 levels in white adipose tissue (WAT), along with increased plasma FGF21 levels. We then assessed the effect of KD on FGF21 signaling in both the liver and WAT. We found that Fgfr4 and Klb (β-klotho) were downregulated in the liver, while Fgfr1 was downregulated in WAT of KD-fed mice. Because inflammation could be one of the mechanisms linking KD to impaired FGF21 signaling, we measured the expression levels of inflammatory markers and macrophage accumulation in WAT and liver and found an increased inflammation and macrophage accumulation in the liver, but surprisingly, a reduction of inflammation in WAT.We also showed that KD enhances lipid accumulation in the liver, which may explain hepatic inflammation and impaired Fgfr4 and Klb expression. In contrast, import of lipids from the circulation was significantly reduced in WAT of KD-fed mice, as suggested by a downregulation of Lpl and Cd36. This was further associated with reduced inflammation in WAT.

Conclusion: Altogether, these results indicate that KD could be beneficial for a given tissue but deleterious for another.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have the following interests: This study was funded in part by Swisslife. There are no patents, products in development or marketed products to declare. This does not alter their adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Ketogenic diet (KD) impairs FGF21 signaling in the liver.
A) KD does not modify Klb (β-Klotho) mRNA expression, but downregulates B) Fgfr4 mRNA expression, with a subsequent reduction of C) phospho-ERK1/2 protein levels. Data are presented as means ± SEM. * P<0.05 (n = 4–6 mice per group).
Fig 2
Fig 2. Ketogenic diet (KD) impairs FGF21 signaling in epididymal white adipose tissue.
A) KD does not affect adiponectin plasma levels; KD downregulates B) Adiponectin, C) Klb (β-Klotho), D) Fgfr1 mRNA expression, and E) phosho-ERK1/2 protein levels in white adipose tissue. Data are presented as means ± SEM. * P<0.05 (n = 4–6 mice per group).
Fig 3
Fig 3. Ketogenic diet (KD) promotes inflammation in the liver while preventing it in epididymal white adipose tissue.
Expression level of inflammatory markers and macrophage recruitment are A) enhanced in the liver of KD-fed mice, while B) reduced in white adipose tissue. Data are presented as means ± SEM. * P<0.05 (n = 6 mice per group).
Fig 4
Fig 4. Ketogenic diet (KD) increases expression of genes involved in lipid accumulation
A) in the liver while it B) reduces it in epididymal white adipose tissue. Data are presented as means ± SEM. * P<0.05 (n = 6 mice per group).

References

    1. Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. Diabetes & metabolism. 2013;39(1):16–26. Epub 2012/12/26. 10.1016/j.diabet.2012.11.002 . - DOI - PubMed
    1. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375(9733):2267–77. 10.1016/S0140-6736(10)60408-4 - DOI - PMC - PubMed
    1. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem. 2005;38(3):203–17. 10.1016/j.clinbiochem.2004.10.014 . - DOI - PubMed
    1. Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annual review of nutrition. 2010;30:273–90. Epub 2010/07/22. 10.1146/annurev.nutr.012809.104726 . - DOI - PMC - PubMed
    1. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. The Journal of endocrinology. 2013;218(3):R25–36. 10.1530/JOE-13-0201 . - DOI - PubMed

Publication types

LinkOut - more resources